JP2014503198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503198A5 JP2014503198A5 JP2013541026A JP2013541026A JP2014503198A5 JP 2014503198 A5 JP2014503198 A5 JP 2014503198A5 JP 2013541026 A JP2013541026 A JP 2013541026A JP 2013541026 A JP2013541026 A JP 2013541026A JP 2014503198 A5 JP2014503198 A5 JP 2014503198A5
- Authority
- JP
- Japan
- Prior art keywords
- bip
- seq
- heavy chain
- human immunoglobulin
- immunoglobulin heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims 13
- 101000899240 Homo sapiens Endoplasmic reticulum chaperone BiP Proteins 0.000 claims 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 4
- 230000002608 insulinlike Effects 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004547 Glucosylceramidase Human genes 0.000 claims 2
- 108010017544 Glucosylceramidase Proteins 0.000 claims 2
- 102100036717 Growth hormone variant Human genes 0.000 claims 2
- 101710191157 Growth hormone variant Proteins 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 2
- 108010076181 Proinsulin Proteins 0.000 claims 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 2
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102100038803 Somatotropin Human genes 0.000 claims 1
- 108050007673 Somatotropin Proteins 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41592610P | 2010-11-22 | 2010-11-22 | |
| US61/415,926 | 2010-11-22 | ||
| PCT/US2011/061862 WO2012071422A2 (en) | 2010-11-22 | 2011-11-22 | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503198A JP2014503198A (ja) | 2014-02-13 |
| JP2014503198A5 true JP2014503198A5 (enExample) | 2015-01-22 |
Family
ID=46146394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541026A Withdrawn JP2014503198A (ja) | 2010-11-22 | 2011-11-22 | 組換え酵素および他のタンパク質のタンパク質発現および分泌を改善する新規シグナル配列 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9279007B2 (enExample) |
| EP (2) | EP3461905B1 (enExample) |
| JP (1) | JP2014503198A (enExample) |
| KR (2) | KR20190060888A (enExample) |
| CN (1) | CN103328649B (enExample) |
| BR (1) | BR112013012671B1 (enExample) |
| CA (1) | CA2818689C (enExample) |
| CY (1) | CY1121049T1 (enExample) |
| DK (2) | DK3461905T3 (enExample) |
| ES (2) | ES2687415T3 (enExample) |
| HR (1) | HRP20181315T1 (enExample) |
| HU (1) | HUE039070T2 (enExample) |
| LT (1) | LT2643468T (enExample) |
| PL (1) | PL2643468T3 (enExample) |
| PT (1) | PT2643468T (enExample) |
| RS (1) | RS57601B1 (enExample) |
| SI (1) | SI2643468T1 (enExample) |
| SM (1) | SMT201800466T1 (enExample) |
| WO (1) | WO2012071422A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3164492T1 (sl) * | 2014-07-03 | 2020-02-28 | F. Hoffmann-La Roche Ag | Sistem polipeptidne ekspresije |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| JP7341900B2 (ja) | 2017-03-03 | 2023-09-11 | オブシディアン セラピューティクス， インコーポレイテッド | 免疫療法のためのｃｄ１９組成物及び方法 |
| EP3635009B1 (en) | 2017-06-07 | 2026-02-25 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| WO2019108924A2 (en) | 2017-11-30 | 2019-06-06 | Amicus Therapeutics, Inc. | Cdkl5 expression variants and cdkl5 fusion proteins |
| IL276464B2 (en) | 2018-02-07 | 2026-01-01 | Regeneron Pharma | Methods and compositions for administering therapeutic protein |
| BR112020021962A2 (pt) * | 2018-04-30 | 2021-01-26 | Amicus Therapeutics, Inc. | construtos para terapia gênica e métodos de uso |
| MA52626A (fr) | 2018-05-17 | 2021-03-24 | Regeneron Pharma | Anticorps anti-cd63, conjugués et leurs utilisations |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020077114A2 (en) | 2018-10-10 | 2020-04-16 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
| EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CN113454227B (zh) * | 2018-12-19 | 2025-05-23 | 维萨梅布有限公司 | 编码蛋白质的rna |
| MX2021010840A (es) | 2019-03-08 | 2022-01-19 | Obsidian Therapeutics Inc | Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable. |
| KR20220004696A (ko) * | 2019-04-30 | 2022-01-11 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 폼페병의 치료에 유용한 조성물 |
| US20220267398A1 (en) | 2019-06-12 | 2022-08-25 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| KR20220044266A (ko) | 2019-06-12 | 2022-04-07 | 옵시디안 테라퓨틱스, 인크. | 조정 가능한 조절을 위한 ca2 조성물 및 방법 |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN112342247B (zh) * | 2020-11-10 | 2022-03-11 | 江苏科技大学 | 一种提高家蚕细胞表达外源蛋白分泌率的方法 |
| KR20230128001A (ko) | 2020-12-01 | 2023-09-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 엔젤만 증후군의 치료를 위한 조성물 및 이의 용도 |
| WO2023086939A1 (en) | 2021-11-12 | 2023-05-19 | Amicus Therapeutics, Inc. | Compositions and methods for treating mucopolysaccharidosis iiia |
| WO2025264978A2 (en) | 2024-06-20 | 2025-12-26 | Amicus Therapeutics, Inc. | Recombinant alpha-galactosidase a proteins and gene therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2352286C (en) * | 1998-11-24 | 2011-07-12 | Bristol-Myers Squibb Company | Intracellular targeted delivery of compounds by 70 kd heat shock protein |
| JP4834554B2 (ja) * | 2003-11-06 | 2011-12-14 | ジェネンコー・インターナショナル・インク | 糸状菌におけるプロテアーゼ抑制剤及びその変異体の発現 |
| DK2007885T3 (da) * | 2006-04-11 | 2010-11-08 | Csl Behring Gmbh | Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider |
-
2011
- 2011-11-22 EP EP18181451.8A patent/EP3461905B1/en active Active
- 2011-11-22 PT PT11843849T patent/PT2643468T/pt unknown
- 2011-11-22 KR KR1020197015057A patent/KR20190060888A/ko not_active Ceased
- 2011-11-22 SM SM20180466T patent/SMT201800466T1/it unknown
- 2011-11-22 ES ES11843849.8T patent/ES2687415T3/es active Active
- 2011-11-22 CA CA2818689A patent/CA2818689C/en active Active
- 2011-11-22 CN CN201180065369.5A patent/CN103328649B/zh active Active
- 2011-11-22 KR KR1020137016110A patent/KR101984318B1/ko active Active
- 2011-11-22 HU HUE11843849A patent/HUE039070T2/hu unknown
- 2011-11-22 DK DK18181451.8T patent/DK3461905T3/da active
- 2011-11-22 DK DK11843849.8T patent/DK2643468T3/en active
- 2011-11-22 SI SI201131554T patent/SI2643468T1/sl unknown
- 2011-11-22 LT LTEP11843849.8T patent/LT2643468T/lt unknown
- 2011-11-22 WO PCT/US2011/061862 patent/WO2012071422A2/en not_active Ceased
- 2011-11-22 BR BR112013012671-0A patent/BR112013012671B1/pt not_active IP Right Cessation
- 2011-11-22 US US13/988,946 patent/US9279007B2/en active Active
- 2011-11-22 HR HRP20181315TT patent/HRP20181315T1/hr unknown
- 2011-11-22 ES ES18181451T patent/ES2829199T3/es active Active
- 2011-11-22 RS RS20180986A patent/RS57601B1/sr unknown
- 2011-11-22 EP EP11843849.8A patent/EP2643468B1/en active Active
- 2011-11-22 PL PL11843849T patent/PL2643468T3/pl unknown
- 2011-11-22 JP JP2013541026A patent/JP2014503198A/ja not_active Withdrawn
-
2018
- 2018-09-12 CY CY181100941T patent/CY1121049T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503198A5 (enExample) | ||
| WO2012071422A3 (en) | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins | |
| JP2005120106A5 (enExample) | ||
| JP2003524587A5 (enExample) | ||
| JP2019521643A5 (enExample) | ||
| DK2190863T3 (en) | New albumin binding compositions, methods and uses | |
| WO2007130455A3 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
| JP2018033454A5 (enExample) | ||
| CY1112334T1 (el) | Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων | |
| WO2007002261A3 (en) | IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF | |
| Gallizia et al. | Production of a soluble and functional recombinant streptavidin inescherichia coli | |
| JP2015212284A5 (enExample) | ||
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| JP2016508143A5 (enExample) | ||
| JP2021500035A5 (enExample) | ||
| RU2016105586A (ru) | Гибридная конструкция, включающая антигенсвязывающий фрагмент, специфичный к сывороточному альбумину и эффекторный компонент, и способы ее получения | |
| JP2008509682A5 (enExample) | ||
| WO2025010376A3 (en) | Nucleic acids, vectors, and cells that encode anti-sp17 antibodies and other sp17 binding proteins | |
| JP2017526625A5 (enExample) | ||
| CN106868025B (zh) | 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法 | |
| CN110903402A (zh) | 一种双特异性融合蛋白及其构建方法与应用 | |
| CN104558181A (zh) | 靶向b淋巴瘤细胞的人源单链抗体 | |
| CN104031134B (zh) | 一种基因治疗用载体蛋白及其制备方法和用途 | |
| JP6199054B2 (ja) | 抗イヌＩｇＥモノクローナル抗体並びに抗イヌＩｇＥモノクローナル抗体の重鎖可変領域及び軽鎖可変領域 | |
| CN118496349A (zh) | 抗猴痘病毒a35r蛋白的单克隆抗体2d7或其抗体片段 |